Metrion Biosciences, the ion channel CRO, and LifeArc, an independent UK medical research charity, extended their ion channel drug discovery collaboration in the field of neuroscience.
Specifically, their project (started in January 2019) aims to identify novel selective small molecule modulators of a specific two-pore domain potassium ion channel target, previously identified as likely to be involved in neurological pathogenesis.
The companies reported that the initial twelve-month collaboration successfully identifies hit compounds and now progresses into hit-to-lead optimization phase.
Read more about Metrion Biosciences here.
More information about LifeArc here.
Image by Gerd Altmann from Pixabay